Abstract: The present invention relates to a polypeptide comprising (a) a first set of six complementarity determining regions (CDRs) configured to bind a first antigen; and (b) (ba) a second set of six CDRs configured to bind a second antigen; or (bb) a ligand capable of binding to a second antigen; wherein (i) said first antigen is selected from Hepatitis B virus (HBV) small surface antigen; HBV medium surface antigen; and HBV large surface antigen; and (ii) said second antigen is selected from surface antigens presented by immune effector cells such as natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). Also provided are compositions for use in a method of treating or preventing HBV infection and/or a condition caused by said HBV infection, said condition caused by said HBV infection being selected from liver cirrhosis and hepatocellular carcinoma.

Abstract: A novel therapeutic strategy for the anti-PD-1 antibody therapy is provided. A pharmaceutical composition which comprises at least one substance selected from the group consisting of the following (i) to (iii) and is administered before, after or simultaneously with the administration of a PD-1 signal inhibitor: (i) ROS generators and substances that regulate downstream signaling pathways thereof, (ii) substances exhibiting an uncoupling effect and substances that regulate downstream signaling pathways thereof, and (iii) amino acids.

Abstract: A method fits reversing immune suppression or immune exhaustion or for treating a disease associated with immune suppression includes: administering a co position to a subject in need of such treatments wherein the composition contains a CD11b modulator that binds specifically to CD11b on a cell to inhibit PD-L1 expression. The CD11b modulator is an antibody or an antigen-binding portion thereof, or a compound as described.

Abstract: Antibodies and antibody fragments that bind to BDCA2 are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to induce death of a plasmacytoid dendritic cell, inhibit production or secretion of inflammatory cytokines and chemokines, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions.

Abstract: The present invention relates to the field of biomedicine and antibody engineering. Specifically, it relates to mono and multispecific multivalent single chain polypeptide molecules and derivatives thereof, preferably to multispecific single chain (tandem) trimerbodies with defined stoichiometry, to nucleic acid sequences and vectors encoding thereof, and host cells expressing the same. It further relates to methods of producing thereof, pharmaceutical compositions, kits, methods of treatment, use as diagnostics or imaging reagents and combination therapies using thereof.

Abstract: The present invention provides methods for inhibiting or attenuating the growth of a tumor that is resistant to a blockade of EGFR, which include administering an EGFR inhibitor, an EGFR inhibitor and a FGFR inhibitor, or an EGFR inhibitor, an FGFR inhibitor and an ErbB3 inhibitor to a subject having a tumor that is or may become resistant to the blockade of EGFR. Blockade of EGFR, FGFR and/or ErbB3 may be effectuated using target specific antibodies or fragments thereof, small molecule tyrosine kinase inhibitors or a combination thereof.

Abstract: Anti-CD122 and/or ?c antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.

Abstract: The present invention relates to immunoglobulin single variable domain sequences that are directed against (as defined herein) OX40L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such immunoglobulin single variable domain sequences. In particular these immunoglobulin single variable domain sequences can block binding of OX40L to OX40. The immunoglobulin single variable domains, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of inflammatory disease and/or disorder such as e.g. asthma, allergic asthma, chronic colitis, Crohn's disease, inflammatory bowel disease, and/or arthrosclerosis.

Abstract: Compositions including an antibody single-chain variable fragment (scFv) conjugate that specifically binds to ROR1 tumor-associated antigen are provided. The anti-ROR1 scFv antibody and conjugates may include a biologically-active molecule. Such conjugates may comprise a chimeric receptor to direct T cells to respond to ROR1 cancer cells, Methods to use the scFV conjugates to target cells expressing ROR1 for therapeutic and diagnostic purposes are also provided.

Abstract: The present invention relates to an esophageal cancer marker and application thereof. The present invention relates to: a marker that includes Glypican-1 or an expression product thereof, or a fragment or derivative thereof, and serves to identify esophageal cancer; a detection agent that includes a substance that binds to Glypican-1 or an expression product thereof; and a composition that includes a Glypican-1 inhibitor and serves to prevent or treat esophageal cancer. Herein, Glypican-1 can be SEQ ID NO: 1 (nucleic acid sequence) or SEQ ID NO: 2 (amino acid sequence), or an equivalent thereof.

Abstract: We have constructed a polynucleotide encoding a bispecific antibody engaging molecule which has one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The polynucleotide is codon optimized for expression in CHO cells. The subunits of the engaging molecules are organized to achieve greater efficiency. These are promising therapeutic agents.

Abstract: Penumbra is the newest member of the tetraspanin superfamily of membrane proteins. A major obstacle in penumbra research has been the lack of monoclonal antibodies against the native penumbra. In this invention, we detail the establishment and characterization of monoclonal antibodies that recognize both human and mouse penumbras on living cells. Furthermore, we created chimeric mouse-human IgG1 antibodies from these mouse monoclonal antibodies. Using these antibodies, we demonstrate for the first time that penumbra is expressed on the surface of virtually all CD19+ or CD20+ B lymphocytes in blood, bone marrow, spleen and lymph nodes. In vivo, these monoclonal antibodies shrank lymphoid follicles in spleen. Thus, these antibodies establish penumbra as a novel B cell marker with a wider range of expression level than CD19 or CD20. These monoclonal antibodies pave the way for new research and potential therapeutic applications in immunology, hematology and oncology.

Abstract: Antibodies that bind the apple 2 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa are described.

Abstract: The present disclosure relates to a novel class of anti-HER2 monoclonal antibodies comprising a homogeneous population of anti-HER2 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-HER2 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.

Abstract: Mice are provided that comprise a reduction or deletion of ADAM6 activity from an endogenous ADAM6 locus, or that lack an endogenous locus encoding a mouse ADAM6 protein, wherein the mice comprise a sequence encoding an ADAM6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic ADAM6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating. Mice and cells with genetically modified immunoglobulin heavy chain loci that comprise an ectopic nucleotide sequence encoding a mouse ADAM6 or functional fragment or homolog or ortholog thereof are also provided.

Abstract: Provided herein are plasma kallikrein antibodies binding to active plasma kallikrein and methods of using such antibodies in treating and preventing hereditary angioedema attack, such method may involve a first treatment period and optionally, a second treatment period. Also provided are methods of using such antibodies in treating hereditary angioedema involving a single dose of the antibody to a subject who has undergone a prior HAE treatment, followed by multiple doses of the same antibody if the subject experiences an HAE attack after the single dose.

Abstract: The present invention relates to methods of treatment by human ADAMTS13 inhibition in circulatory assist device induced haemorrhagic complication such as a bleeding disorder, in particular, bleeding after left ventricular assist device implantation. The present invention further relates to specific monoclonal antibodies inhibiting ADAMTS13 function.

Abstract: The invention relates to nucleic acid constructs for expression in mice for the production of heavy chain only antibodies and VH domains, transgenic mice, related methods and uses.

Abstract: The present invention relates to a monoclonal antibody specific to porcine circovirus 2 (PCV2) and a method for diagnosing post-weaning multi-systemic wasting syndrome (PMWS) using the same. More specifically, the present invention relates to monoclonal antibodies C4-1 and C4-8 of scFV-human C? fusion recombinant protein, which specifically binds to a decoy epitope of porcine circovirus 2, and to a method for diagnosing post-weaning multi-systemic wasting syndrome using the same. The monoclonal antibody of the present invention makes it possible to determine whether an antibody against PCV2 is a neutralizing antibody by a vaccine antigen or an antibody induced by immune decoy.

Abstract: A heterodimer molecule based on CH3, and a preparation method therefor and a use thereof. By comprehensively considering various interactions between molecules, for example, an ionic action, a hydrophobic interaction and a spatial action, a preferred Fc mutant sequence being more inclined to form a heterodimer rather than a homodimer is screened, and accordingly, the yield of the heterodimer molecule is greatly improved, thereby creating conditions for the preparation of bispecific molecules and the like.

Abstract: A method of manufacturing a cellooligosaccharide containing an oligomer having a degree of polymerization of from 3 to 6, the method includes performing a reaction involving heating and hydrolyzing plant biomass in coexistence with a carbon catalyst and water under such a condition that a temperature-time product over a range of from 170° C. to 230° C. in a graph for showing a relationship between a reaction temperature on an axis of ordinate and a reaction time on an axis of abscissa is from 80° C.·min to 365° C.·min. The maximum reaction temperature (X) and the retention time (Y) at the maximum reaction temperature satisfy a relationship represented by the following expressions (1) to (3). Y>?0.

Abstract: A method for manufacturing a shaped cross-linked hyaluronic acid product including the step of subjecting a non-cross-linked precipitated hyaluronic acid substrate in a desired shape to a single cross-linking reaction in a liquid medium having a pH of 11.5 or higher and including one or more polyfunctional cross-linking agent(s) and an amount of one or more organic solvent(s) giving precipitating conditions for hyaluronic acid, under suitable conditions to obtain a precipitated, shaped cross-linked hyaluronic acid product having a degree of modification of 1-40 cross-linking agent units per 1000 disaccharide units.

Abstract: The present invention relates to a process for separating natural rubber deriving from non-Hevea type plants, in the form of solid crumbs, from solutions in an organic solvent system including it, where said organic solvent system may comprise at least one nonpolar organic solvent, or a mixture of at least one non-polar organic solvent and at least one polar organic solvent, and the concomitant removal of said organic solvent system from said rubber, where the aforementioned process comprises subjecting said solution to a stripping stage by means of water vapor, in presence of a dispersing system, separating the aforementioned crumbs of natural rubber from the liquid phase, obtained through the stripping stage, and subjecting said crumbs to drying.

Abstract: The present invention relates to an olefin polymerization process comprising polymerization of at least one olefin monomer in one or more polymerization reactors. In addition, the present invention relates to a system for vapor phase polymerization of at least one polymerizable monomer.

Abstract: A method for producing a solid catalyst component (Aa) for ?-olefin polymerization, which includes: bringing components (A1) to (A4) into contact with one another in an inert solvent; and without washing the contact product with an inert solvent, aging the contact product by keeping for a holding time of 3 days or more and 180 days or less, regarding the time point that all of the components (A1) to (A4) first come into contact, as a starting point.

Abstract: A process for preparing a procatalyst for polymerization of olefins, comprising contacting a magnesium-containing support with a halogen-containing titanium compound, a first internal electron donor represented by Formula A, a second internal electron donor represented by Formula B, and an activator; wherein the molar ratio of the first internal donor to the second internal donor is between 0.01 and 0.7; wherein in Formula A each R80 group is independently a substituted or unsubstituted aromatic group; and R81, R82, R83, R84, R85, R86 and R87 are each independently selected from a hydrogen or a hydrocarbyl group; wherein in Formula B R51 and R52 are each independently selected from a hydrogen or a hydrocarbyl group; and R53 and R54 are each independently selected from hydrogen, a halide or a hydrocarbyl group.

Abstract: The present invention provides an external electron donor composition comprising essentially of monoether as activity limiting agent for polymerization of olefins along with alkoxy silane as selectivity controlling agent, wherein mole percentage of the alkoxy silane to monoether is from 1 to 100.

Abstract: A method for producing a (meth)acryloyl-terminated polyisobutylene polymer includes a step 1 of polymerizing an isobutylene monomer under the presence of a Lewis acid catalyst to prepare a halogen-terminated polyisobutylene polymer (B), a step 2 of reacting the halogen-terminated polyisobutylene polymer (B) with a compound (C) having a halogen group and a phenoxy group under the presence a Lewis acid catalyst to prepare a halogenated phenoxyalkyl-terminated polyisobutylene polymer (D), and a step 3 of reacting the halogenated phenoxyalkyl-terminated polyisobutylene polymer (D) with an acrylic acid compound (E) to prepare the (meth)acryloyl-terminated polyisobutylene polymer (A).

Abstract: Provided is a composition comprising droplets distributed in an aqueous medium, wherein the droplets comprise one or more boronic acids, and wherein the aqueous medium comprises polyvinyl alcohol.

Abstract: Polycationic polymeric antimicrobial surfactant and polymeric biocompatible antimicrobial surfactant compositions are useful in dispersing various compounds in a carrier liquid. The polycationic polymeric antimicrobial surfactant and polymeric biocompatible antimicrobial surfactant compositions employ polymers having both hydrophilic domains and hydrophobic domains so that the compositions can disperse particles such as polymer particles or droplets in a continuous phase as well as provide stable dispersions that have not been provided before. The antimicrobial properties of the compositions provide much-needed capabilities of fighting infectious agents such as bacteria and viruses in a wide spectrum of products such as paint, adhesives, and coatings. Methods of using these compositions as well as methods of making products using the compositions are disclosed.

Abstract: Embodiments of 1,4-polybutadiene rubber compositions useful at low temperatures are provided, wherein the 1,4-polybutadiene incorporated therein comprises a cis content of at least 85 to about 92%, a vinyl content of at about 1% to about 5%, and a trans content of about 3 to about 12%, and wherein the 1,4-polybutadiene has an enthalpy of melting ?Hm of about 5 to about 25 J/g° C. as measured via differential scanning calorimetry (DSC).

Abstract: A procatalyst for polymerization of olefins, which procatalyst is based on a magnesium compound of the formula MgR?R? wherein R? is an alkoxide or aryloxide group and R? is an alkoxide or aryloxide group or halogen, an activator being a monoester and an internal donor represented by a compound according to formula A: as described herein. Also described is a polymerization catalyst system comprising the procatalyst, a co-catalyst and optionally an external electron donor; a process of making a polyolefin, by contacting an olefin with the catalyst system; a polyolefin, obtained by or obtainable by the process; and a polyolefin, having a molecular weight distribution of between 4 and 15, a molecular weight (Mw) of between 300,000 to 1,500,000 g/mol, a melting temperature of more than 150° C., a value for the xylene solubles of less than 4 wt. % and a shaped article therefrom.

Abstract: A copolymer comprising a copolymer chain A bearing a function B selected from the group consisting of the functions B1 and B2, the copolymer chain A being a copolymer chain comprising monomer units M1 and monomer units M2, M1 being a conjugated diene and M2 being a monomer selected from the group consisting of ?-monoolefins, ethylene and mixtures thereof, B1 being selected from the group consisting of N(SiMe3)2; N(SiMe2CH2CH2SiMe2); para-C6H4(NMe2); para-C6H4(OMe); para-C6H4(N(SiMe3)2); ortho-CH2-C6H4NMe2; ortho-CH2-C6H4OMe; C6F5; C3F7; C6F13; CH(OCH2CH2O); B2 being a function that is derived from B1, is provided. Such a copolymer is synthesized by using a transfer agent bearing the function B1 and a carbon-metal bond, the metal being an alkaline-earth metal, zinc or aluminium.

Abstract: A propylene 1-hexene copolymer containing from about 5.5 to about 9.0% by weight, based upon the total weight of the copolymer, of 1-hexene derived units having: a) two melting temperature peaks in the DSC plot having a difference in height ranging from 0 to 5 mW; b) the higher melting temperature, measured by DSC, ranging from about 141.0° C. to about 151.0° C.; and c) Melt Flow Rate (MFR, measured according to ASTM D 1238, 230° C./2.16 kg) from about 3.5 to about 8.0 g/10 min.

Abstract: A process for producing an allylic alcohol functionalized butyl rubber involves contacting an epoxidized butyl rubber with benzoic acid, an analogue of benzoic acid or a C1-C7 alkanoic acid. The process and a polymer compound comprising the epoxidized butyl rubber and the benzoic acid, analogue of benzoic acid or a C1-C7 alkanoic acid provide a cost effective route to a polar functionalized butyl rubber, particularly to butyl rubber comprising allylic alcohol functional groups.

Abstract: High Mooney viscosity elastomers having low volatiles content, and processes for producing such elastomers, are provided herein. In particular aspects, the elastomers are metallocene-catalyzed elastomers, such as mEPDM elastomers. Processes for producing such elastomers include devolatilization of an elastomer stream comprising such elastomers, using a kneader. The kneader is counterintuitively operated such that the internal agitating paddles rotate at relatively low speeds. It is believed these low speeds help maintain the elastomer stream as a toffee-like composition, preventing the elastomer stream within the kneader from becoming a crumbly composition, which is difficult to devolatilize.

Abstract: There is provided a thermosetting resin composition. A resin composition, comprising: (A) component, (B) component, and a solvent, wherein the content of the (B) component is 0.1 to 5.

Abstract: A method comprising contacting at least one metal salt of an organic acid with at least one aromatic compound in a reaction zone under conditions suitable for the formation of a polymer, wherein the metal salt of an organic acid comprises a metal and at least one unsaturated organic acid moiety. A composition comprising polystyrene and a metal salt of cinnamic acid. An article made from a composition comprising polystyrene and a metal salt of cinnamic acid. A composition comprising polystyrene and a salt of a fatty acid. An article made from a composition comprising polystyrene and a salt of a fatty acid.

Abstract: Provided is a method of making droplets distributed in an aqueous medium comprising bringing into contact (i) an organic solution comprising 0.

Abstract: “The present invention relates to a polymeric composition comprising a polymer comprising monomers of methyl methacrylate and methacrylic acid. In particular the present invention relates to a process for making a polymeric composition suitable for moulded objects, said polymeric composition is comprising monomers of methyl methacrylate and methacrylic acid. The present invention concerns also process for making a moulded object comprising a polymer comprising monomers of methyl methacrylate and methacrylic acid. The present invention concerns also moulded object comprising a polymer comprising monomers of methyl methacrylate and methacrylic acid.

Abstract: A process for preparing an aqueous dispersion of a polymer P (aqueous polymer P dispersion) by free-radically initiated aqueous emulsion polymerization.

Abstract: A silicone pressure sensitive adhesive with amphiphilic copolymers for maintaining adhesion in a moist environment. The amphiphilic copolymers for silicone adhesives include at least one silicone moiety and at least one hydrophilic segment. Such adhesives are applicable to securing medical devices to human skin.

Abstract: The present invention relates to a method of preparing a polyrotaxane, said method comprising: performing a radical copolymerization of at least (a) a first polymerizable monomer having a stopper group, and of at least (b) a second polymerizable monomer, wherein said second monomer is complexed by a ring-shaped molecule; wherein during said copolymerization a copolymer threading said ring-shaped molecule is formed, wherein during said copolymerization said first monomer having a stopper group is incorporated into the chain of said copolymer at least partially between the ends thereof, and wherein said stopper groups prevent said ring-shaped molecule from disassembling from the copolymer; and wherein the amount of said first monomer having a stopper group is of from 0.1 mol % to 20 mol % based on 100 mol % of the total amount of polymerizable monomers. The present invention also relates to polyrotaxanes which can be prepared by using such a method.

Abstract: An object of the present invention is to provide a self-assembly composition for pattern formation, which is capable of forming a favorable phase-separated structure even in the case of forming a large size pattern. In addition, another object of the present invention is to provide a self-assembly composition for pattern formation, which is capable of forming a pattern by a simple process, with no need for preparation of a under layer, etc., upon formation of a fine pattern structure. The present invention relates to a self-assembly composition for pattern formation, which comprises a block copolymer comprising a polymerization unit (a) comprising two or more units consisting of at least one type selected from a glucose unit and a xylose unit, and a polymerization unit (b) comprising two or more units consisting of at least one type selected from an aromatic ring-containing unit, a silicon-containing unit and a metal-containing unit.

Abstract: A biodegradable and biocompatible hydrogel of tunable conductivity is provided. The hydrogel includes a polymer conjugated to a bio-ionic liquid. The mechanical and electrical properties of the hydrogel can be varied by altering the ratio of the polymer to the bio-ionic liquid in the conjugated polymer. These properties can be varied also by changing the percent weight of the conjugated polymer in the hydrogel. A method for preparing the hydrogel is also provided.

Abstract: A polyol composition includes a first polyol (A-I) having a number average molecular weight of 1000 to 10000; and 35 to 60% by weight of a core-shell polymer (B) including a core layer and a shell layer. The core-shell polymer is uniformly dispersed in the first polyol (A-I) and has a volume average particle diameter of 0.01 to 0.6 ?m. A polymer constituting the shell layer has a solubility parameter of 9.30 to 10.20 (cal/cm3)1/2 and comprises at least 25 to 90% by weight of an alkyl (meth)acrylate unit having a linear or branched alkyl group of 4 to 10 carbons.

Abstract: Embodiments of the present disclosure are directed to polyolefm grafted polydiene polymers, wherein the polyolefin grafted polydiene polymers comprises a polydiene having a polydiene polymer backbone, a polyolefm, and at least one sulfur containing functionalizing agent which grafts the polyolefin onto at least one non-terminal position on the polydiene polymer backbone.

Abstract: A novel photocurable resin composition including: a polymer with a weight average molecular weight of 1,000 to 50,000, the polymer having a structural unit of formula (1), and having a structure of formula (2) at an end: wherein X is a C1-6 alkyl group, vinyl group, allyl group, or glycidyl group; m and n are each independently 0 or 1; Q is a divalent hydrocarbon group having a carbon atom number of 1 to 16; Z is a divalent linking group having a carbon atom number of 1 to 4, wherein the divalent linking group is attached to the —O— group in formula (1); and R1 is a hydrogen atom or methyl group; a radical photopolymerization initiator; and a solvent.

Abstract: The invention provides a hydrophilized polydiorganosiloxane vinylic crosslinker which comprises (1) a polydiorganosiloxane polymer chain comprising dimethylsiloxane units and hydrophilized siloxane units each having one methyl substituent and one monovalent C4-C40 organic radical substituent having two to six hydroxyl groups, wherein the molar ratio of the hydrophilized siloxane units to the dimethylsiloxane units is from about 0.035 to about 0.15, and (2) two terminal (meth)acryloyl groups. The hydrophilized polydiorganosiloxane vinylic crosslinker has a number average molecular weight of from about 3000 Daltons to about 80,000 Daltons. The present invention is also related to a silicone hydrogel contact lens, which comprises repeating units derived from a hydrophilized polydiorganosiloxane vinylic crosslinker of the invention.

Abstract: Provided is a protective member for coil springs, including a tube main body that covers a coil spring of a suspension, wherein the tube main body is made of thermoplastic polyurethane that includes a prepolymer and a chain extender, wherein the prepolymer includes diisocyanate and a polyol, wherein a molar ratio of the diisocyanate to a sum of the polyol and the chain extender (diisocyanate/(polyol+chain extender)) is 1.025 to 1.040 and a molar ratio of the chain extender to the polyol (chain extender/polyol) is 6 to 3.8.